Synovus Financial Corp Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Synovus Financial Corp lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 20.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 591,111 shares of the biopharmaceutical company's stock after selling 149,616 shares during the quarter. Synovus Financial Corp's holdings in Pfizer were worth $15,683,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Nordea Investment Management AB boosted its holdings in shares of Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI lifted its position in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares during the last quarter. Copley Financial Group Inc. purchased a new stake in Pfizer in the third quarter worth approximately $577,000. Mcdonald Partners LLC grew its position in Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Finally, Merit Financial Group LLC raised its stake in shares of Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock worth $3,395,000 after acquiring an additional 48,397 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on PFE shares. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group decreased their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.07.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Trading Up 0.4 %

Shares of NYSE PFE traded up $0.09 during midday trading on Thursday, hitting $22.13. 53,854,504 shares of the company traded hands, compared to its average volume of 40,471,352. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The stock has a 50-day moving average price of $25.02 and a 200 day moving average price of $26.28. The firm has a market cap of $125.50 billion, a P/E ratio of 15.69, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.